Shenzhen Beimei Pharmaceutical Co., Ltd. ( Beimei Pharma ), has been granted as a National High-tech Enterprise and a Shenzhen Innovation-driven SME Enterprise. Beimei Pharma specializes in pediatric prescription medicines,  integrating full-spectrum capabilities of R&D, manufacture, commercialization and global cooperation, driven by the core strategy of self-development and global collaboration via in-licensing, asset purchase acquisition etc. Synergizing with the manufacture base in Liangyungang to fulfil sufficient production and global supply of diversified special formulations for children's medications, Beimei Pharma is aiming to provide pediatric patients with high-quality and full range of medicines.

Beimei Pharma has more than 40 pediatric drug products in portfolio and pipeline, including 6 approved drugs launched in the market, and several innovative drugs with global rights and independent intellectual property rights. The current pipeline covers the therapeutic fields of dermatology, respiratory, gastroenterology, anti-infection, neurology, neonatal, endocrinology, etc. Beimei  Pharma aquired the asset of TWYNEO® in China (including Hong Kong, Macau, and Taiwan) and Israel on May 15th, 2024, strengthening its dermatology pipeline. TWYNEO® is the first and only FDA-approved fixed-dose combination of tretinoin and benzoyl peroxide cream for the treatment of acne vulgaris in adults and pediatric patients nine years of age and older.

Beimei Pharma has established long-term partnerships with multiple large international pharmaceutical companies, such as Hetero, Cipla, Deva, Dr. Reddy’s, LTS, MedPharma, Synthon, EMP, NTC、Syrimed, Sol-Gel, etc.

Beimei Pharma has completed the Angel Round, Round A, Round B/B+ and Round C financing with hundreds of millions of RMB. Beimei Pharma gained recognition from many well-known investment institutions, including Efung Capital and the industrial parties.